The FDA delivered a second rejection of Capricor’s Duchenne cell therapy, deramiocel, citing “serious data integrity violations” that the agency said compromised the study findings. The decision marks another regulatory setback for a program that had already faced rejection since 2025. The agency’s stated basis centers on data quality and integrity rather than efficacy interpretation, which can stall clinical development by requiring additional analyses, rework of endpoints, or new submission components. For Duchenne stakeholders, the key issue is how quickly Capricor can remediate the cited dataset problems and re-engage with the regulator. The rejection also underscores heightened scrutiny on manufacturing, analytics, and supporting documentation for advanced cell therapies as they advance toward pivotal evidence.
Get the Daily Brief